Who we are
We are the largest privately owned and independent plasma fractionator in the world. Our medicines are high-quality human proteins sourced from human plasma and human cell lines.
:quality(80)/f/54881/1091x726/64cad4c78b/sweden2.jpg)
:quality(80)/f/54881/1091x726/de87bb1dba/zz_64cad4c78b_blurred.jpg)
About us
Our five values -Ownership, Integrity, Leadership, Sustainability and Entrepreneurship- guide our patient-oriented corporate culture. We aspire to embody these values in everything we do.
Diseases & therapies
We develop and manufacture medicines for patients in three therapeutic areas: haematology, immunotherapy and critical care.
Research & development
We carry out pre-clinical and clinical research to develop new products and ensure that they are safe to use. In 2018, we invested €87 million in our research and development work.
Our locations
We are located in 31 countries and our medicines help people in 115 countries around the world. We have seven R&D and six manufacturing sites in Europe and North America.